Related Experiment Video
Updated: May 19, 2026
12:28
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
Evolution of source EEG synchronization in early Alzheimer's disease
Maria G Knyazeva1, Cristian Carmeli, Alireza Khadivi
1LREN, Department of Clinical Neuroscience, Centre Hospitalier Universitaire Vaudois (CHUV), and University of Lausanne, Lausanne, Switzerland. Maria.Knyazeva@chuv.ch
Neurobiology of Aging
|August 21, 2012
Summary
Alzheimer
Area of Science:
- Neuroscience
- Biomarkers
- Electroencephalography
Background:
- Alzheimer's disease (AD) impairs brain network connectivity.
- Identifying reliable biomarkers for AD progression is crucial.
Purpose of the Study:
- To assess the S-estimator, a measure of brain synchronization, as a potential Alzheimer's disease biomarker.
- To investigate changes in EEG synchronization over time in relation to AD progression.
Main Methods:
- Analyzed electroencephalogram (EEG) source data from 15 mild AD patients and 15 controls.
- Measured the S-estimator, a multivariate intraregional synchronization metric, at diagnosis and after one year.
- Compared synchronization changes between rapidly and slowly progressing AD patients.
Main Results:
- Alzheimer's disease (AD) patients exhibited hyposynchronization in medial temporal/frontal regions and hypersynchronization in posterior regions compared to controls.
- Overall S-estimator did not change significantly over one year in either group.
- Rapidly progressing AD patients showed a significant decrease in synchronization over time, particularly in the left frontotemporal cortex.
Conclusions:
- Changes in EEG synchronization over time correlate with Alzheimer's disease (AD) progression rate.
- The S-estimator's temporal evolution may serve as a cost-effective biomarker for AD.
- Source EEG synchronization offers insights into AD's dynamic impact on brain networks.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...